ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma

Lu, Q.*; Huang, H.; Tang, S.; Wang, Y.; Yang, D-H*广州军区广州总医院; 南方医科大学
DRUGS OF TODAY2021-9DOI: 10.1358/dot.2021.57.9.3306767
2被引5阅读
引用收藏
分享

摘要

Diffuse large B-cell lymphoma (DLBCL) is a common lymphoproliferative and invasive disease. The current first-line regimen for the treatment of DLBCL is R-CHOP, which is the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. R-CHOP has significantly improved the outcome of DLBCL in the last decades. However, 30-40% of patients fail the therapy with R-CHOP. Salvage chemotherapy for relapsed/refractory DLBCL (R/R DLBCL) is extremely challenging, especially in elderly patients. In July 2020, a new monoclonal antibody, tafasitamab, was approved by the Food and Drug Administration (FDA) of the United States for the treatment of DLBCL. Tafasitamab is an anti-CD19 monoclonal antibody which is Fc-enhanced and humanized. CD19 is typically expressed in the developing B cells in non-Hodgkin's lymphomas. Tafasitamab has been proven to be a safe and valid treatment and recommended to be used in combination with lenalidomide in adults with R/R DLBCL who are ineligible for autologous stem cell transplantation (ASCT). This article evaluates the pharmacodynamics, pharmacokinetics, mechanism of action and the clinical application of tafasitamab in the treatment of DLBCL, particularly in R/R DLBCL. The advantages and disadvantages of using tafasitamab and chimeric antigen receptor T cells (CAR-T cells) targeting CD19 are also discussed.

学科与关键词

关键词
TafasitamabLenalidomideB-cell lymphomaFc-engineered anti-CD19 antibodiesCombination therapyMonoclonal antibodiesNon-Hodgkin's lymphomasHematological malignancies
相关
加载中…
  • Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
    Qu, Changju*; Zou, Rui; Wang, Peng; Zhu, Qian; Kang, Liqing; Ping, Nana; Xia, Fan; Liu, Hailing; Kong, Danqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*Frontiers in Immunology, 2022, 13: 969660.被引 8
  • Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥ 2 Prior Therapies
    Song, Yu-Qin; Zhang, Hui-Lai; Huang, Hui-Qiang; Zhang, Qing-Yuan; Jing, Hong-Mei; Wang, Chao; Wu, Chun; Li, Dong-Hang; Dai, Yu; Humphrey, Kathryn; Zhu, Jun64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 1
  • Lenalidomide in Diffuse Large B-Cell Lymphoma
    Catherine Thieblemont; Marie-Hélène Delfau-Larue; Bertrand CoiffierAdvances in Hematology, 2012, 2012: 1-8.
查看全部 →

发表信息

论文状态
公开发表
期刊
DRUGS OF TODAY
发表日期
2021-09
卷期
第 57 卷, 第 9 期
页码
571-580
DOI
10.1358/dot.2021.57.9.3306767
语言
ENGLISH
期刊收录
NSL
期刊等级
4区
成果收录
SCIE

作者

  • L

    Lu, Q. (通讯) (第一作者)

    southern med univ · guangzhou gen hosp

  • H

    Huang, H.

    southern med univ

查看全部 5 位作者收起作者
  • T

    Tang, S.

    southern med univ

  • W

    Wang, Y.

    southern med univ

  • Y

    Yang, D-H (通讯)

    new

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417